Research Article
Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment
Table 1
Baseline demographic characteristics of RA patients treated with tocilizumab (TCZ) and methotrexate (MTX).
| | TCZ pts.
() | MTX pts.
() |
| | Female, (%) | 36 (90) | 12 (60) | | Age (years)—mean ± SD | 55 ± 11 | 56 ± 14 | | Disease duration (months)—mean ± SD | 9.8 ± 4.3 | 6.7 ± 3.0 | | BMI (kg/m2)—mean ± SD | 26.5 ± 4.2 | 27.2 ± 5.0 | | Smokers, (%) | 11 (27.5) | 5 (25) | | Arterial hypertension, (%) | 12 (30) | 7 (35) | | Diabetes, (%) | 6 (15) | 3 (15) | | RF positive, (%) | 32 (80) | 16 (80) | | ACPA positive, (%) | 33 (82.5) | 17 (85) | | Combination treatment, (%) | | | | Steroids | 14 (35) | 6 (30) | | csDMARD | | | | MTX | 28 (70) | 20 (100) | | LFM | 8 (20) | | | SSZ | 4 (10) | |
|
|
ACPA: anticitrullinated peptide antibody; csDMARD: conventional synthetic disease-modifying antirheumatic drug; MTX: methotrexate; LFM: leflunomide; SSZ: sulfasalazine; RF: rheumatoid factor. . |
